These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35688094)

  • 1. Prevention, treatment, and palliative care: The relative value of health improvements under alternative evaluation frameworks.
    Hammitt JK
    J Health Econ; 2022 Jul; 84():102643. PubMed ID: 35688094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The social value of mortality risk reduction: VSL versus the social welfare function approach.
    Adler MD; Hammitt JK; Treich N
    J Health Econ; 2014 May; 35():82-93. PubMed ID: 24699210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fair innings? The utilitarian and prioritarian value of risk reduction over a whole lifetime.
    Adler MD; Ferranna M; Hammitt JK; Treich N
    J Health Econ; 2021 Jan; 75():102412. PubMed ID: 33373936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring social welfare functions and violation of monotonicity: an example from inequalities in health.
    Abasolo I; Tsuchiya A
    J Health Econ; 2004 Mar; 23(2):313-29; discussion 332-4. PubMed ID: 15019757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the (Near) Equivalence of Welfarist and Extra-Welfarist Methods to Value Healthcare With Implications for Assessing Equity.
    Phelps CE
    Value Health; 2023 Nov; 26(11):1601-1607. PubMed ID: 37597613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?
    Dolan P; Edlin R
    J Health Econ; 2002 Sep; 21(5):827-43. PubMed ID: 12349884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fairness in cost-benefit analysis: A methodology for health technology assessment.
    Samson AL; Schokkaert E; Thébaut C; Dormont B; Fleurbaey M; Luchini S; Van de Voorde C
    Health Econ; 2018 Jan; 27(1):102-114. PubMed ID: 28620934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discounting for health effects in cost-benefit and cost-effectiveness analysis.
    Gravelle H; Smith D
    Health Econ; 2001 Oct; 10(7):587-99. PubMed ID: 11747043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness to pay for QALY: perspectives and contexts in Japan.
    Igarashi A; Goto R; Yoneyama-Hirozane M
    J Med Econ; 2019 Oct; 22(10):1041-1046. PubMed ID: 31262236
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?
    Culyer AJ; Chalkidou K
    Value Health; 2019 Jan; 22(1):99-103. PubMed ID: 30661640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a Responsibility-Catering Prioritarian Ethical Theory of Risk.
    Wikman-Svahn P; Lindblom L
    Sci Eng Ethics; 2019 Jun; 25(3):655-670. PubMed ID: 29508127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axiomatic foundations for cost-effectiveness analysis.
    Canning D
    Health Econ; 2013 Dec; 22(12):1405-16. PubMed ID: 23440955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allocation of resources between smoking cessation methods and lovastatin treatment of hypercholesterolaemia: based on cost effectiveness and the social welfare function.
    Plans-Rubió P
    Pharmacoeconomics; 2004; 22(1):55-69. PubMed ID: 14720082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A welfare-theoretic model consistent with the practice of cost-effectiveness analysis and its implications.
    Basu A
    J Health Econ; 2020 Mar; 70():102287. PubMed ID: 31972535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the possibility of a bridge between CBA and CEA: comments on a paper by Dolan and Edlin.
    Hansen BO; Hougaard JL; Keiding H; Østerdal LP
    J Health Econ; 2004 Sep; 23(5):887-98. PubMed ID: 15353184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-, under- and misuse of pain treatment in Germany.
    Dietl M; Korczak D
    GMS Health Technol Assess; 2011 Apr; 7():Doc03. PubMed ID: 21522485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the welfare theoretic foundation of cost-effectiveness analysis-the case when survival is not affected.
    Liljas B
    Eur J Health Econ; 2010 Feb; 11(1):5-13. PubMed ID: 19255794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-social welfare functions: a reply to Hansen et al.
    Edlin R
    J Health Econ; 2004 Sep; 23(5):899-905. PubMed ID: 15353185
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.